KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Capital Expenditures (2016 - 2026)

Thermo Fisher Scientific filings provide 18 years of Capital Expenditures readings, the most recent being $376.0 million for Q1 2026.

  • On a quarterly basis, Capital Expenditures rose 3.87% to $376.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.5 billion, a 8.76% increase, with the full-year FY2025 number at $1.5 billion, up 8.93% from a year prior.
  • Capital Expenditures hit $376.0 million in Q1 2026 for Thermo Fisher Scientific, down from $465.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $640.0 million in Q2 2022 to a low of $272.0 million in Q3 2024.
  • Median Capital Expenditures over the past 5 years was $404.0 million (2025), compared with a mean of $413.1 million.
  • Biggest five-year swings in Capital Expenditures: tumbled 43.87% in 2023 and later soared 48.53% in 2025.
  • Thermo Fisher Scientific's Capital Expenditures stood at $550.0 million in 2022, then fell by 26.36% to $405.0 million in 2023, then increased by 18.52% to $480.0 million in 2024, then decreased by 3.12% to $465.0 million in 2025, then fell by 19.14% to $376.0 million in 2026.
  • The last three reported values for Capital Expenditures were $376.0 million (Q1 2026), $465.0 million (Q4 2025), and $404.0 million (Q3 2025) per Business Quant data.